Diagnostic Work-Up and Management of Short-Rib Thoracic Dysplasia
All fetuses or newborns with suspected short-rib thoracic dysplasia require immediate comprehensive skeletal radiographic survey, clinical examination for extraskeletal manifestations (particularly renal, hepatic, and retinal), and molecular genetic testing via whole-exome sequencing or targeted skeletal dysplasia gene panels focusing on DYNC2H1, DYNC2I1, and DYNC2I2 genes.
Diagnostic Work-Up Algorithm
Prenatal Detection
Ultrasound findings as early as 12-13 weeks gestation can identify SRTD, with key diagnostic features including:
- Shortened ribs with narrow thorax (most consistent finding) 1, 2
- Shortened long bones (femur length/abdominal circumference ratio <0.16 in 91% of lethal cases) 3
- Polydactyly (hands and/or feet) - present in approximately 50% of cases 4
- Thoracic circumference measurements relative to femur length 3
Critical pitfall: Some SRTD subtypes (particularly SRTD11) may present with prominent limb shortening and polydactyly as primary findings while thoracic abnormalities remain subtle 5. Do not exclude SRTD based solely on less obvious thoracic findings.
Genetic Testing Strategy
Perform whole-exome sequencing or targeted skeletal dysplasia gene panel immediately upon suspicion 6, 7. The most commonly implicated genes are:
- DYNC2H1 (SRTD3) - most frequent, with c.44delC as common variant 4
- DYNC2I1 (SRTD8) 4
- DYNC2I2 (SRTD11) 5
Compound heterozygous mutations are the typical inheritance pattern 2, 7. Genetic confirmation enables accurate recurrence risk counseling (25% for autosomal recessive inheritance) and permits preimplantation genetic diagnosis for future pregnancies 3.
Postnatal/Post-Termination Evaluation
Mandatory full diagnostic work-up includes 3:
- Complete skeletal radiographic survey (anteroposterior and lateral views)
- Clinical photographs (external phenotype documentation)
- Autopsy with systematic evaluation of:
- Kidneys (cystic dysplasia common in ciliopathies)
- Liver (fibrosis/ductal abnormalities)
- Retina (dystrophy)
- Lungs (hypoplasia assessment)
Store DNA from affected fetuses even if parents decline full autopsy, as this permits future molecular diagnosis refinement and accurate genetic counseling 3.
Management Recommendations
Prenatal Management
When SRTD is diagnosed prenatally with confirmed lethal genotype-phenotype correlation, offer termination of pregnancy with full informed consent 2. Early diagnosis (12-13 weeks) provides less traumatic decision-making compared to mid-trimester diagnosis 2.
For pregnancies continued to term or uncertain prognosis cases, deliver at tertiary care center with neonatal intensive care and genetics expertise 3.
Newborn Management
All newborns with suspected skeletal dysplasia require immediate specialist evaluation regardless of prenatal diagnosis 3. The guideline explicitly states this applies even when lethal dysplasia was suspected prenatally, as:
- Prenatal ultrasound diagnosis is challenging given phenotypic variability
- Specific diagnosis confirmation enables appropriate palliative measures or medical intervention
- Natural history-altering therapies are increasingly available for specific skeletal dysplasias 3
Refer immediately to specialized skeletal dysplasia center for:
- Clinical examination by geneticist
- Complete skeletal survey
- Molecular confirmation if not obtained prenatally
- Assessment of extraskeletal manifestations (renal ultrasound, ophthalmology, hepatic function)
Genetic Counseling
Provide definitive recurrence risk counseling (25% for confirmed autosomal recessive DYNC2H1/DYNC2I1/DYNC2I2 variants) and offer:
- Preimplantation genetic diagnosis for future pregnancies 3
- Early first-trimester ultrasound surveillance (12-13 weeks) in subsequent pregnancies 2
- Chorionic villus sampling at 11-13 weeks if molecular diagnosis confirmed 2
The combination of early ultrasound screening and genetic testing enables diagnosis by 12-13 weeks, providing couples with earlier, less traumatic reproductive decision-making 1, 2.